Eligibility of real-world patients for aspirin primary prevention trials in cardiovascular disease
Compared with trial-ineligible populations within the same age and sex strata, RCTs recruited people of varying CVD risk but often excluded people at high risk of bleeding or non-CVD death, highlighting that many trials may overestimate the net benefit of aspirin for primary prevention.
Authors
- Daniel R. Morales
- Peter Hanlon
- David A McAllister
- Michael Holder
- Bruce Guthrie
Institutions
- University of Dundee (GB)
- Scotland's Rural College (GB)
- Genomics (United Kingdom) (GB)
- University of Glasgow (GB)
- University of Edinburgh (GB)
Publication Details
- Journal
- BMC Medicine
- Published
- 2026-01-27
- DOI
- https://doi.org/10.1186/s12916-026-04654-w
- Primary Topic
- Antiplatelet Therapy and Cardiovascular Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00